Janus Henderson Group PLC Sells 9,257 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Janus Henderson Group PLC reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 210,080 shares of the biopharmaceutical company's stock after selling 9,257 shares during the quarter. Janus Henderson Group PLC owned 0.16% of Alnylam Pharmaceuticals worth $49,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $41,529,000. Truist Financial Corp lifted its holdings in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock valued at $1,035,000 after acquiring an additional 2,539 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock valued at $67,464,000 after acquiring an additional 8,462 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock valued at $4,687,000 after acquiring an additional 2,285 shares during the period. 92.97% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ALNY shares. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an "equal weight" rating in a report on Friday, March 21st. William Blair restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Stifel Nicolaus upped their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research report on Monday, March 31st. Finally, Royal Bank of Canada upped their price target on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $266.86 on Wednesday. The stock has a market capitalization of $34.80 billion, a PE ratio of -122.98 and a beta of 0.17. The business has a 50 day simple moving average of $251.33 and a two-hundred day simple moving average of $253.69. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1-year low of $144.73 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This trade represents a 1.47% decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,392 shares of company stock worth $1,875,627 in the last quarter. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.